Diabetes Mellitus, Type 2FrequencyNCT01277471
Effect of Meal Frequency on Insulin Resistance in Subjects With Type 2 Diabetes
A study testing Meal frequency (6 meals vs. 2 meals/day) and 6 meals/day followed by 2 meals/day in people with Diabetes Mellitus, Type 2, run by Institute for Clinical and Experimental Medicine at 1 site in Czechia.
Trial summary
Aims and priorities of the project The purpose of this study is to 1. test the effect of frequency of meals (six vs. two meals daily with the same daily caloric restriction of -500 kcal/day) on insulin sensitivity, insulin secretion, and hepatic fat content. 2. Read more about this study
- Who is it for?
- Ages 30 to 70 years
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Meal frequency (6 meals vs. 2 meals/day) and 6 meals/day followed by 2 meals/day
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteCzechia
- Study dates
- Dec 2010to Oct 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Type 2 diabetes for more than 1 year
- Treatment of T2D. Oral hypoglycemic agents stable for the last 3 months
- HbA1c ≥4.2 and ≤10.5% (IFCC)
- Agek 30-70 years
- Body Mass Index (kg/m2) between 27 and 50
- Willingness to follow both different dietary regimens
- The patient has at least 3 of the symptoms of the metabolic syndrome
Who cannot join
- Alcoholism or drug abuse
- Pregnancy, lactation
- Nonstable medication for diabetes, hypertension or dyslipidemia in the last 3 months
- Diagnosis of type 1 diabetes
- Weight loss or weight gain in the last 3 months (> 5% of the total body weight)
- Cardiostimulant
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Meal Frequency on Insulin Resistance, Insulin Secretion, and Hepatic Fat Content in Subjects With Type 2 Diabetes
Aims and priorities of the project The purpose of this study is to
- test the effect of frequency of meals (six vs. two meals daily with the same daily caloric restriction of -500 kcal/day) on insulin sensitivity, insulin secretion, and hepatic fat content.
- characterize some of the mechanisms of action of different frequencies of meals (amount of visceral fat, hepatic fat content, serum concentrations of adipokines, gut hormones, oxidation stress markers).
- test the ability of the participants to maintain hypocaloric diet on both regimens when educated and left to prepare their meals alone in comparison with those for whom all meals during the study will be provided.
Read more
It will be a randomized, crossover study, where 50 individuals with type 2 diabetes will change in a random order two regimens: six, and two meals a day. Each testing period will take three months.
Glucose and lipid metabolism and its regulation will be thoroughly tested at start, and after each 3-months-period (meal test, hyperinsulinemic isoglycemic clamp, indirect calorimetry, MRI scan of the liver, DXA scan, serum concentration determination of selected adipokines, gut hormones, and oxidation stress markers).
Hypothesis The investigators hypothesize that low plasma insulin levels (as achieved by periods of fasting) will reduce insulin resistance and hepatic lipid content. In contrast, frequent meals (and consequent higher plasma levels of insulin) will predispose to non-alcoholic fatty liver disease and insulin resistance. The investigators further hypothesize that the participants will increase their caloric intake with increased meal frequency (in spite of thorough education) when left to prepare their meals in comparison with those for whom all meals will be provided.
Read the detailed description
Aims and priorities of the project The purpose of this study is to
- test the effect of frequency of meals (six vs. two meals daily with the same daily caloric restriction of -500 kcal/day) on insulin sensitivity, insulin secretion, and hepatic fat content.
- characterize some of the mechanisms of action of different frequencies of meals (amount of visceral fat, hepatic fat content, serum concentrations of adipokines, gut hormones, oxidation stress markers).
- test the ability of the participants to maintain hypocaloric diet on both regimens when educated and left to prepare their meals alone in comparison with those for whom all meals during the study will be provided.
It will be a randomized, crossover study, where 50 individuals with type 2 diabetes will change in a random order two regimens: six, and two meals a day. Each testing period will take three months.
Glucose and lipid metabolism and its regulation will be thoroughly tested at start, and after each 3-months-period (meal test, hyperinsulinemic isoglycemic clamp, indirect calorimetry, MRI scan of the liver, DXA scan, serum concentration determination of selected adipokines, gut hormones, and oxidation stress markers).
Hypothesis The investigators hypothesize that low plasma insulin levels (as achieved by periods of fasting) will reduce insulin resistance and hepatic lipid content. In contrast, frequent meals (and consequent higher plasma levels of insulin) will predispose to non-alcoholic fatty liver disease and insulin resistance. The investigators further hypothesize that the participants will increase their caloric intake with increased meal frequency (in spite of thorough education) when left to prepare their meals in comparison with those for whom all meals will be provided.
Key words Insulin resistance, meal frequency, type 2 diabetes mellitus, non-alcoholic fatty liver disease, adipokines, gut hormones, oxidative stress Methodology Study design: the investigators will use the design of a randomized, crossover study, where 50 individuals with type 2 diabetes will change in a random order the frequency of their meals: six, and two meals a day. Caloric restriction will be the same (-500 kcal/day). Each testing period will take three months. For one half of the participants all meals during the study will be provided. The other half will be thoroughly educated how to maintain their daily caloric intake during both regimens and they will prepare their meals alone.
Study group: 50 individuals with type 2 diabetes treated by diet only or oral hypoglycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent (Appendix 1).
Regimens: On the six-meals-per-day-regimen, participants will be asked to divide their total caloric intake into six meals and to eat every two or three hours. On the two-meals-per-day-regimen, they will divide their total caloric intake into two meals: the first meal will be eaten between 6 and 10 a.m., the second one between noon and 4 p.m.
Physical activity: Participants will be asked not to change their exercise habits during the study. Physical activity will be monitored using pedometers and standardized questionnaires: International Physical Activity Questionnaire (IPAQ), and Baecke questionnaire.
Procedures:
At the beginning (week 0), and at the end of every 3 months (week 12, and 24), the following procedures and measurements will be performed at each subject (three times in each subject):
- Common anthropometric investigations (body weight, BMI, waist and hip circumference), blood samples will be taken for laboratory assessments (common laboratory tests, parameters of glucose and lipid metabolism, chosen adipokines, oxidative stress markers, gut hormones, fatty acid composition in serum phospholipids etc.- see analytic methods).
- Meal test for glucose tolerance assessment after standard breakfast /baguette Crocodille Cheese Gourmet - 180g, energy 452,8 Kcal/1895,7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g/. Blood samples for the assessment of glycemia, C- peptide, immunoreactive insulin (IRI) will be taken in 0, 30, 60, 120 and 180 minutes after breakfast.
- Hyperinsulinemic (1 mU/kg/min) isoglycemic clamp (HIC) 3 hours long with indirect calorimetry. This method allows exact quantification of insulin resistance and energy substrates utilisation.
- MRI (magnetic resonance imaging) scan of the liver to measure the hepatic fat content.
- DXA (Dual energy X-ray absorptiometry) scan to measure total body composition and fat content.
- Insulin secretion and glucose control will be measured during a one-day-stay in the hospital at the end of each regimen. Blood samples will be taken every three hours during the whole day. Urine will be collected during the whole day to measure microalbuminuria and C-peptide waste.
Analytic methods:
Plasma concentrations of selected adipokines (resistin, adiponectin total, HMW- adiponectin, TNFalfa and leptin) and other cytokines and proteins (FABP) will be measured enzymatically using standard kits (ELISA, Linco, USA). Plasma levels of gut hormones will be measured enzymatically usig standard kits (Milliplex, Millipore, USA). Parameters of lipid peroxidation will be determined according to the levels of TBARS by the reaction with thiobarbituric acid and according to the levels of conjugated dienes.
The level of reduced and oxidised glutathione will be determined using HPLC method with fluorescence detection. Ascorbic acid will be determined spectrophotometric reaction with dinitrophenylhydrazine. Concentrations of a- and g-tocopherol in serum will be determined by reverse-phase high performance liquid chromatography (HPLC) with fluorescence detection according to the modified method of Catignani and Biery. The activity of SOD will be analyzed by the reaction of blocking nitrotethrazolium blue reduction and nitrophormasane formation. Catalase activity measurement is based on the ability of H2O2 to produce with ammonium molybdate the color complex detected spectrophotometrically. The activity of gluthathione peroxidase will be monitored by oxidation velocity of gluthathione by Ellman reagent. Serum glucose will be analysed using the glucose-oxidase method Beckman Analyzer (Beckman Instruments Inc., Fullerton, CA, USA), IRI will be determined by radioimmunoassay using an IMMUNOTECH Insulin IRMA kit (IMMUNOTECH as, Prague, Czech Republic), C-peptide using an IMMUNOTECH C-Peptide IRMA kit (IMMUNOTECH as, Prague, Czech Republic) and glycated hemoglobin will be measured by a Bio-Rad Haemoglobin A1c Column Test (Bio-Rad Laboratories GmbH, Munich, Germany).
Fatty acid pattern in serum phospholipids will be measured after lipids extraction according to Folch and separation of lipid fractions by thin-layer chromatography. The methylesters of fatty acids will be separated by gas chromatography.
Eventual effects of different meal frequency regimens will be evaluated due to chosen gene polymorphisms.
Statistic analysis: Will be done with the use of ANOVA tests, pair and unpair t- tests and other statistic methods using standard statistic programs. Estimate of the number of subjects to be recruited was done using power analysis of repeated measurements via statistic software PASS 2005 (Number Cruncher Statistical Systems, Kaysville, UT, USA). Factors included in this model are interindividual factors (control vs. experimental group), intraindividual factors (individual time stadium in the study) and interaction between factors (divergence degree between time profiles in control and experimental group).
Time frame: December 2010-February 2011 recruitment of the participants March 2011 start of the study Group A: 12 weeks 6 meals/day followed by additional 12 weeks of 2 meal/day Group B: 12 weeks 2 meals/day followed by additional 12 weeks of 6 meal/day September 2011 end of the study
All measurements will be done at start, week 12 and week 24.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Meal frequency (6 meals vs. 2 meals/day), 6 meals/day followed by 2 meals/day
- Keywords
- meal frequency, type two diabetes
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Meal frequency (6 meals vs. 2 meals/day)Behavioural
6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
6 meals/day followed by 2 meals/dayBehavioural
2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
| Study group | Role | What they receive |
|---|---|---|
| Arm A: 6 and 2 meals/day | Experimental | 6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day) Receives: Behavioral: Meal frequency (6 meals vs. 2 meals/day) |
| Arm B: 2 and 6 meals/day | Active comparator | 2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day) Receives: Behavioral: 6 meals/day followed by 2 meals/day |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Insulin Resistance
Insulin Resistance measured by hyperinsulinemic isoglycemic clamp
Measured: Insulin resistance will be measured at weeks 0, 12 and 24. Change from baseline to 12 weeks and from week 12 to week 24 will be assessed.
Secondary outcomes (6)
hepatic fat content
hepatic fat content measured by magnetic resonance spectroscopy
Measured: Hepatic fat content will be measured at weeks 0, 12 and 24. Change from baseline to 12 weeks and from week 12 to week 24 will be assessed.
Insulin Secretion
Insulin secretion measured by meal test (standard breakfast)
Measured: Insulin secretion will be measured at weeks 0, 12 and 24. Change from baseline to 12 weeks and from week 12 to week 24 will be assessed.
insulin sensitivity
Insulin sensitivity will be measured using the isoglycemic hyperinsulinemic clamp.
Measured: Insulin secretion will be measured at weeks 0, 12 and 24.
Fatty acid composition in serum phospholipids
Fatty acid composition in serum phospholipids will be measured by gas liquid chromatography.
Measured: Weeks 0,12 and 24
Gastrointestinal peptides
Gastrointestinal peptides will be measured in response to a standard breakfast at times 0,30,60,120 and 180.
Measured: Weeks 0, 12 and 24
Oxidative stress markers and AGEs
Oxidative stress markers and AGEs will be measured in a fasting state.
Measured: weeks 0,12 and 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jan 2011 (estimated)
- Study startDec 2010
- Primary completionOct 2011
- Study completionOct 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institute for Clinical and Experimental Medicine
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Hana Kahleova, Institute for Clinical and Experimental Medicine
- Investigators
- Terezie Pelikanova, Prof., MD, Study chair, Institute for Clinical and Experimental Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01277471
- Sponsor's protocol ID
- 3142
- Other IDs
- NT/11238-4
- Acronym
- Frequency
- Status last verified
- Apr 2012
- First submitted
- 6 Jan 2011
- Last updated
- 6 Apr 2012
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Kahleova H, Belinova L, Malinska H, Oliyarnyk O, Trnovska J, Skop V, Kazdova L, Dezortova M, Hajek M, Tura A, Hill M, Pelikanova T. Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study. Diabetologia. 2014 Aug;57(8):1552-60. doi: 10.1007/s00125-014-3253-5. Epub 2014 May 18.
PubMed 24838678
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Meal Frequency on Insulin Resistance, Insulin Secretion, and Hepatic Fat Content in Subjects With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT01277471
- Acronym / sponsor ID
- Frequency / 3142
- Conditions
- Diabetes Mellitus, Type 2
- Keywords
- meal frequency, type two diabetes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Institute for Clinical and Experimental MedicineOther government
- Study start
- Dec 2010
- Primary completion
- Oct 2011 (actual)
- Study completion
- Oct 2011 (actual)
- First posted
- 17 Jan 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aims and priorities of the project The purpose of this study is to
- test the effect of frequency of meals (six vs. two meals daily with the same daily caloric restriction of -500 kcal/day) on insulin sensitivity, insulin secretion, and hepatic fat content.
- characterize some of the mechanisms of action of different frequencies of meals (amount of visceral fat, hepatic fat content, serum concentrations of adipokines, gut hormones, oxidation stress markers).
- test the ability of the participants to maintain hypocaloric diet on both regimens when educated and left to prepare their meals alone in comparison with those for whom all meals during the study will be provided.
It will be a randomized, crossover study, where 50 individuals with type 2 diabetes will change in a random order two regimens: six, and two meals a day. Each testing period will take three months.
Glucose and lipid metabolism and its regulation will be thoroughly tested at start, and after each 3-months-period (meal test, hyperinsulinemic isoglycemic clamp, indirect calorimetry, MRI scan of the liver, DXA scan, serum concentration determination of selected adipokines, gut hormones, and oxidation stress markers).
Hypothesis The investigators hypothesize that low plasma insulin levels (as achieved by periods of fasting) will reduce insulin resistance and hepatic lipid content. In contrast, frequent meals (and consequent higher plasma levels of insulin) will predispose to non-alcoholic fatty liver disease and insulin resistance. The investigators further hypothesize that the participants will increase their caloric intake with increased meal frequency (in spite of thorough education) when left to prepare their meals in comparison with those for whom all meals will be provided.
Detailed description
Aims and priorities of the project The purpose of this study is to
- test the effect of frequency of meals (six vs. two meals daily with the same daily caloric restriction of -500 kcal/day) on insulin sensitivity, insulin secretion, and hepatic fat content.
- characterize some of the mechanisms of action of different frequencies of meals (amount of visceral fat, hepatic fat content, serum concentrations of adipokines, gut hormones, oxidation stress markers).
- test the ability of the participants to maintain hypocaloric diet on both regimens when educated and left to prepare their meals alone in comparison with those for whom all meals during the study will be provided.
It will be a randomized, crossover study, where 50 individuals with type 2 diabetes will change in a random order two regimens: six, and two meals a day. Each testing period will take three months.
Glucose and lipid metabolism and its regulation will be thoroughly tested at start, and after each 3-months-period (meal test, hyperinsulinemic isoglycemic clamp, indirect calorimetry, MRI scan of the liver, DXA scan, serum concentration determination of selected adipokines, gut hormones, and oxidation stress markers).
Hypothesis The investigators hypothesize that low plasma insulin levels (as achieved by periods of fasting) will reduce insulin resistance and hepatic lipid content. In contrast, frequent meals (and consequent higher plasma levels of insulin) will predispose to non-alcoholic fatty liver disease and insulin resistance. The investigators further hypothesize that the participants will increase their caloric intake with increased meal frequency (in spite of thorough education) when left to prepare their meals in comparison with those for whom all meals will be provided.
Key words Insulin resistance, meal frequency, type 2 diabetes mellitus, non-alcoholic fatty liver disease, adipokines, gut hormones, oxidative stress Methodology Study design: the investigators will use the design of a randomized, crossover study, where 50 individuals with type 2 diabetes will change in a random order the frequency of their meals: six, and two meals a day. Caloric restriction will be the same (-500 kcal/day). Each testing period will take three months. For one half of the participants all meals during the study will be provided. The other half will be thoroughly educated how to maintain their daily caloric intake during both regimens and they will prepare their meals alone.
Study group: 50 individuals with type 2 diabetes treated by diet only or oral hypoglycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent (Appendix 1).
Regimens: On the six-meals-per-day-regimen, participants will be asked to divide their total caloric intake into six meals and to eat every two or three hours. On the two-meals-per-day-regimen, they will divide their total caloric intake into two meals: the first meal will be eaten between 6 and 10 a.m., the second one between noon and 4 p.m.
Physical activity: Participants will be asked not to change their exercise habits during the study. Physical activity will be monitored using pedometers and standardized questionnaires: International Physical Activity Questionnaire (IPAQ), and Baecke questionnaire.
Procedures:
At the beginning (week 0), and at the end of every 3 months (week 12, and 24), the following procedures and measurements will be performed at each subject (three times in each subject):
- Common anthropometric investigations (body weight, BMI, waist and hip circumference), blood samples will be taken for laboratory assessments (common laboratory tests, parameters of glucose and lipid metabolism, chosen adipokines, oxidative stress markers, gut hormones, fatty acid composition in serum phospholipids etc.- see analytic methods).
- Meal test for glucose tolerance assessment after standard breakfast /baguette Crocodille Cheese Gourmet - 180g, energy 452,8 Kcal/1895,7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g/. Blood samples for the assessment of glycemia, C- peptide, immunoreactive insulin (IRI) will be taken in 0, 30, 60, 120 and 180 minutes after breakfast.
- Hyperinsulinemic (1 mU/kg/min) isoglycemic clamp (HIC) 3 hours long with indirect calorimetry. This method allows exact quantification of insulin resistance and energy substrates utilisation.
- MRI (magnetic resonance imaging) scan of the liver to measure the hepatic fat content.
- DXA (Dual energy X-ray absorptiometry) scan to measure total body composition and fat content.
- Insulin secretion and glucose control will be measured during a one-day-stay in the hospital at the end of each regimen. Blood samples will be taken every three hours during the whole day. Urine will be collected during the whole day to measure microalbuminuria and C-peptide waste.
Analytic methods:
Plasma concentrations of selected adipokines (resistin, adiponectin total, HMW- adiponectin, TNFalfa and leptin) and other cytokines and proteins (FABP) will be measured enzymatically using standard kits (ELISA, Linco, USA). Plasma levels of gut hormones will be measured enzymatically usig standard kits (Milliplex, Millipore, USA). Parameters of lipid peroxidation will be determined according to the levels of TBARS by the reaction with thiobarbituric acid and according to the levels of conjugated dienes.
The level of reduced and oxidised glutathione will be determined using HPLC method with fluorescence detection. Ascorbic acid will be determined spectrophotometric reaction with dinitrophenylhydrazine. Concentrations of a- and g-tocopherol in serum will be determined by reverse-phase high performance liquid chromatography (HPLC) with fluorescence detection according to the modified method of Catignani and Biery. The activity of SOD will be analyzed by the reaction of blocking nitrotethrazolium blue reduction and nitrophormasane formation. Catalase activity measurement is based on the ability of H2O2 to produce with ammonium molybdate the color complex detected spectrophotometrically. The activity of gluthathione peroxidase will be monitored by oxidation velocity of gluthathione by Ellman reagent. Serum glucose will be analysed using the glucose-oxidase method Beckman Analyzer (Beckman Instruments Inc., Fullerton, CA, USA), IRI will be determined by radioimmunoassay using an IMMUNOTECH Insulin IRMA kit (IMMUNOTECH as, Prague, Czech Republic), C-peptide using an IMMUNOTECH C-Peptide IRMA kit (IMMUNOTECH as, Prague, Czech Republic) and glycated hemoglobin will be measured by a Bio-Rad Haemoglobin A1c Column Test (Bio-Rad Laboratories GmbH, Munich, Germany).
Fatty acid pattern in serum phospholipids will be measured after lipids extraction according to Folch and separation of lipid fractions by thin-layer chromatography. The methylesters of fatty acids will be separated by gas chromatography.
Eventual effects of different meal frequency regimens will be evaluated due to chosen gene polymorphisms.
Statistic analysis: Will be done with the use of ANOVA tests, pair and unpair t- tests and other statistic methods using standard statistic programs. Estimate of the number of subjects to be recruited was done using power analysis of repeated measurements via statistic software PASS 2005 (Number Cruncher Statistical Systems, Kaysville, UT, USA). Factors included in this model are interindividual factors (control vs. experimental group), intraindividual factors (individual time stadium in the study) and interaction between factors (divergence degree between time profiles in control and experimental group).
Time frame: December 2010-February 2011 recruitment of the participants March 2011 start of the study Group A: 12 weeks 6 meals/day followed by additional 12 weeks of 2 meal/day Group B: 12 weeks 2 meals/day followed by additional 12 weeks of 6 meal/day September 2011 end of the study
All measurements will be done at start, week 12 and week 24.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A: 6 and 2 meals/day | Experimental | Behavioral: Meal frequency (6 meals vs. 2 meals/day)6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day) |
| Arm B: 2 and 6 meals/day | Active comparator | Behavioral: 6 meals/day followed by 2 meals/day2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day) |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Type 2 diabetes for more than 1 year
- Treatment of T2D. Oral hypoglycemic agents stable for the last 3 months
- HbA1c ≥4.2 and ≤10.5% (IFCC)
- Agek 30-70 years
- Body Mass Index (kg/m2) between 27 and 50
Key exclusion criteria (6 listed)
- Alcoholism or drug abuse
- Pregnancy, lactation
- Nonstable medication for diabetes, hypertension or dyslipidemia in the last 3 months
- Diagnosis of type 1 diabetes
- Weight loss or weight gain in the last 3 months (> 5% of the total body weight)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Meal frequency (6 meals vs. 2 meals/day)6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day) | Behavioural | Arm A: 6 and 2 meals/day |
| 6 meals/day followed by 2 meals/day2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day) | Behavioural | Arm B: 2 and 6 meals/day |
Primary outcome
Change in Insulin Resistance
Time frame: Insulin resistance will be measured at weeks 0, 12 and 24. Change from baseline to 12 weeks and from week 12 to week 24 will be assessed.
Insulin Resistance measured by hyperinsulinemic isoglycemic clamp
6 secondary outcomes
hepatic fat content
Time frame: Hepatic fat content will be measured at weeks 0, 12 and 24. Change from baseline to 12 weeks and from week 12 to week 24 will be assessed.
Insulin Secretion
Time frame: Insulin secretion will be measured at weeks 0, 12 and 24. Change from baseline to 12 weeks and from week 12 to week 24 will be assessed.
insulin sensitivity
Time frame: Insulin secretion will be measured at weeks 0, 12 and 24.
Fatty acid composition in serum phospholipids
Time frame: Weeks 0,12 and 24
Gastrointestinal peptides
Time frame: Weeks 0, 12 and 24
Oxidative stress markers and AGEs
Time frame: weeks 0,12 and 24
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2012.
- Derived from this study: PubMed 24838678Kahleova H, Belinova L, Malinska H, Oliyarnyk O, Trnovska J, Skop V, Kazdova L, Dezortova M, Hajek M, Tura A, Hill M, Pelikanova T. Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study. Diabetologia. 2014 Aug;57(8):1552-60. doi: 10.1007/s00125-014-3253-5. Epub 2014 May 18.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Terezie Pelikanova, Prof., MD study chair
Institute for Clinical and Experimental Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Meal frequency (6 meals vs. 2 meals/day) and 6 meals/day followed by 2 meals/day in people with Diabetes Mellitus, Type 2, run by Institute for Clinical and Experimental Medicine at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Apr 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Insulin Resistance (time frame: Insulin resistance will be measured at weeks 0, 12 and 24. Change from baseline to 12 weeks and from week 12 to week 24 will be assessed.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01277471, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2012.